Xycota Biosciences

Target the repair pathway. Not the trip. Preclinical neuroscience: a low-dose psilocybin capsule designed to be taken at home. First question: mild PTSD.

[Xycota Biosciences @xycota]

4/4 Preclinical and investigational. Not approved by any regulatory authority. Forward-looking statements involve risks and uncertainties; actual results may differ. Not an offer to buy or sell securities. #PTSDResearch #Veterans

[Xycota Biosciences @xycota]

1/4 For veterans, first responders, and everyday adults living with PTSD, chronic stress physically prunes synaptic connections in the prefrontal cortex, as studied in preclinical rat models of BDNF/TrkB signaling.

[Xycota Biosciences @xycota]

3/4 Observed in rats, not people. Whether a sub-perceptual capsule (XYCO-02) helps adults with mild PTSD is what we aim to test.
Join the movement: https://t.co/N1bWCKpxhD

[Xycota Biosciences @xycota]

This Veterans Day, honoring service means confronting what follows too many home.

29% of Iraq/Afghanistan vets face PTSD, yet only 27% screening positive get care. Trauma is biology, not weakness.

Free, no-login PTSD Hub: https://t.co/2ugPNbuWaZ
#VeteransDay #PTSD
$BDPT

[Xycota Biosciences @xycota]

4/4 Preclinical and investigational. Not approved by any regulatory authority. #Neuroscience #Biotech

[Xycota Biosciences @xycota]

1/4 Two switches. In a 2026 rat study (Ascone et al., Neuropsychopharmacology, DOI: 10.1038/s41386-026-02361-x), repeated low-dose oral psilocybin (0.1 mg/kg p.o.) rescued object-recognition memory in male Fmr1 rats.

[Xycota Biosciences @xycota]

3/4 Observed in rats. Not people. A Fragile X rat model is not human PTSD, and whether a sub-perceptual oral capsule engages TrkB in humans has not yet been tested.
https://t.co/Y8oe8JDXGB

[Xycota Biosciences @xycota]

Target the repair pathway. Not the trip.

How Xycota Biosciences is testing whether the TrkB-BDNF synaptic repair pathway (Ascone et al., 2026) can be engaged by a sub-perceptual 1.5 mg oral capsule (XYCO-02) at home: https://t.co/Uc4U4foxtx

Preclinical/investigational.

[Xycota Biosciences @xycota]

Target the repair pathway. Not the trip.

In the 2026 Fragile X rat study (Ascone et al.), memory rescue persisted under 5-HT2A blockade and disappeared under TrkB blockade. Next question: mild PTSD in humans (XYCO-02). https://t.co/1ucscqsMYW

Preclinical; not approved.

[Xycota Biosciences @xycota]

@BioadaptivesInc Welcome BDPT Shareholders: https://t.co/H0losdlmtM

[Xycota Biosciences @xycota]

@BioadaptivesInc Hello BDPT shareholders - please follow us for more and join our movement: https://t.co/H0losdlmtM
$BDPT #bioadaptives

[Xycota Biosciences @xycota]

$BDPT - We welcome BDPT Shareholders to follow us!

[Xycota Biosciences @xycota]

1/5 BioAdaptives, Inc. (OTCID: BDPT) and Xycota Biosciences signed a definitive acquisition agreement (Oct 29, 2026; Form 8-K Nov 4). Signed, not closed.

Press release: https://t.co/nsuNBV5uwM

[Xycota Biosciences @xycota]

5/5 Preclinical and investigational. Not approved by any regulatory authority. Forward-looking statements involve risks and uncertainties; actual results may differ. Not medical advice and not an offer or solicitation to buy or sell any security. #Neuroscience #Biotech

[Xycota Biosciences @xycota]

4/5 Next step for XYCO-02: complete the Canadian Clinical Trial Application and submit with KGK Science for a proposed 28-day double-blind at-home study in mild PTSD.
https://t.co/4RjpUwn9U3

[Xycota Biosciences @xycota]

5/5 Preclinical and investigational. Not approved by any regulatory authority. Forward-looking statements involve risks and uncertainties; actual results may differ. Not medical advice and not an offer or solicitation to buy or sell any security. #Neuroscience #Biotech

[Xycota Biosciences @xycota]

2/5 In a 2026 rat study (Ascone et al., Neuropsychopharmacology, DOI: 10.1038/s41386-026-02361-x), repeated low-dose oral psilocybin rescued object-recognition memory in Fmr1 rats. Blocking 5-HT2A or 5-HT1A did not stop the rescue. Blocking TrkB abolished it.

[Xycota Biosciences @xycota]

4/5 Next step for XYCO-02: complete the Canadian Clinical Trial Application and submit with KGK Science for a proposed 28-day double-blind at-home study in mild PTSD.
https://t.co/4RjpUwn9U3